2025年1月22日,复旦大学附属肿瘤医院研究团队在期刊《Cell Reports Medicine》上发表了题为“Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2− breast cancer”的研究论文。在这项研究中,团队利用由579名HR+/HER2-乳腺癌患者组成的多组学队列(其中200名患者拥有...
因此,迫切需要预测 HR+/HER2− 乳腺癌患者复发的风险。 2025 年 1 月 22 日,复旦大学附属肿瘤医院肖毅副研究员、邵志敏教授、江一舟教授等人在 Cell 子刊Cell Reports Medicine上发表了题为:Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer 的...
这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associate...
unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2020;180(3):597-609.
HER2 and Breast Cancer — A Phenomenal Success Story. Daniel F. Hayes. University of Michigan Rogel Cancer Center, Ann Arbor. During the past three decades, the risk of dying from breast cancer in the United States has declined by nearly half, thanks to a combination of screening and early...
在过去 HER2靶向治疗成果的基础上,对这些新概念的研究和这些方法的使用将最终导致持续的进展。 参考文献:1.Sandra M. Swain, Mythili Shastry & Erika Hamilton Targeting HER2-positive breast cancer: advances and future directions Nature Reviews Drug Discovery(2022)...
[15]https://www.linkedin.com/pulse/twenty-years-miracle-breast-cancer-drug-sue-desmond-hellmann-md-mph/ [16]https://www.cancer.gov/research/progress/discovery/HER2 [17] Hong S, Gu Y, Gao Z, et al. EGFR inhibitor-driven endoplasmicreticulumstress-mediated injury on intestinalepithelial cells...
[4]Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022 Jun 23. [5]Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressin...
以提高对CDK4/6抑制的理解以及HR阳性、HER2阴性乳腺癌的当代管理。参考来源：Final Results from PALLAS Study Confirm Lack of Benefit in Adding Palbociclib to ET in Early HR+, HER2- Breast Cancer 注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。
Carey LA. Breast cancer: HER2--a good addic- tion. Nature reviews. Clin Oncol 2012; 9: 196- 197.Carey, L.A. Breast cancer: Her2--A good addiction. Nat. Rev. Clin. Oncol. 2012, 9, 196-197. [CrossRef] [PubMed]Carey LA. Breast cancer: HER2-a good addiction. Nat Rev Clin ...